StocksMedium•9 November 2026•
1 min read
Foghorn Therapeutics Reports Q3 2026 GAAP EPS of $0.80
Key Facts
1Foghorn Therapeutics reported a GAAP EPS of $0.80 for the quarter.
2The company's revenue reached $83.5 million for the reported period.
Foghorn Therapeutics reported a GAAP EPS of $0.80 for the third quarter of 2026. According to Seeking Alpha, the company's revenue reached $83.5 million for the reported period.
Research and development expenses were $18.8 million for the three months ended September 30, 2026, compared to $20.0 million for the same period in 2025. FHTX closed at $1.87 on November 6, 2026, after reaching a day high of $1.94.